Division of Endocrinology and Metabolism, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Diabetes and Thyroid Center, Theptarin Hospital, Bangkok, Thailand.
Curr Med Res Opin. 2020 Oct;36(10):1601-1610. doi: 10.1080/03007995.2020.1808454. Epub 2020 Aug 26.
Sodium-glucose co-transporter-2 inhibitors (SGLT2is) are widely used to improve both glycemic control and cardio-renal outcomes. We aim to evaluate the real-life clinical effectiveness, safety and outcomes of SGLT2is in Thai adults with type 2 diabetes mellitus (T2DM).
This was a retrospective study involving adults with T2DM who were treated with SGLT2is for ≥3 months.
Among 1159 participants (women 52.6%; age: 61.1 ± 10.9 years; body mass index: 28.7 ± 5.2 kg/m), 65.1%, 34.3% and 0.6% received dapagliflozin, empagliflozin and canagliflozin, respectively. Median SGLT2i treatment duration was 15 (IQR, 8-23) months. Of the patients, 16.5%, 6.4%, 4.9% and 1.6% had pre-existing coronary artery disease, stroke, heart failure and peripheral arterial disease, respectively. Mean HbA1c decreased by 0.7% (95% CI, -1.0 to -0.4) from a baseline of 8.3 ± 1.5%. At 24 months, body weight, and systolic and diastolic blood pressure decreased significantly from the baseline average of 2.5 kg, 3.5 mmHg and 2.4 mmHg, respectively. The median decline in eGFR was -1.3 ml/min/1.73 m/year. The incidences of pollakiuria, genital tract infection, urinary tract infection and hypoglycemia were 7.2%, 2.8%, 2.2% and 0.9%, respectively. No participants developed diabetic ketoacidosis during the observation period.
SGLT2is improved cardiometabolic parameters in Thai adults, clinically confirming findings in controlled trials.
钠-葡萄糖协同转运蛋白 2 抑制剂（SGLT2is）被广泛用于改善血糖控制和心肾结局。我们旨在评估 SGLT2is 在泰国 2 型糖尿病（T2DM）成人中的真实临床疗效、安全性和结局。
这是一项回顾性研究，纳入了接受 SGLT2is 治疗≥3 个月的 T2DM 成人患者。
在 1159 名参与者中（女性占 52.6%；年龄：61.1±10.9 岁；体重指数：28.7±5.2kg/m²），分别有 65.1%、34.3%和 0.6%的患者接受了达格列净、恩格列净和卡格列净治疗。SGLT2i 治疗的中位时间为 15（IQR，8-23）个月。患者中有 16.5%、6.4%、4.9%和 1.6%分别患有冠心病、卒、心力衰竭和外周动脉疾病。与基线时的 8.3±1.5%相比，平均 HbA1c 降低了 0.7%（95%CI，-1.0 至-0.4）。在 24 个月时，体重、收缩压和舒张压较基线平均水平分别显著下降 2.5kg、3.5mmHg 和 2.4mmHg。eGFR 的中位数下降了 1.3ml/min/1.73m/year。多尿、生殖道感染、尿路感染和低血糖的发生率分别为 7.2%、2.8%、2.2%和 0.9%。在观察期间，没有参与者发生糖尿病酮症酸中毒。
SGLT2is 改善了泰国成年人的心血管代谢参数，临床证实了对照试验中的发现。
